Immunic, INC 8-K filings

Immunic, Inc. announced the appointment of Elena Ridloff to its Board of Directors and provided an update on its Phase 3 trials for vidofludimus calcium in multiple sclerosis, with top-line data expected by year-end.

Immunic, Inc. released an updated presentation on July 14, 2026, detailing its development programs, clinical trial progress, and future outlook.

Immunic, Inc. announced the resignation of Tamar Howson from its Board of Directors and Compensation Committee due to retirement, and the subsequent appointment of CEO Erik Lundgren as a Class II director.

Immunic, Inc. held its annual meeting where stockholders approved an amendment to increase shares available under its 2019 Omnibus Equity Incentive Plan and ratified the appointment of Baker Tilly as its auditor.

Immunic, Inc. presented new post-hoc analysis data from its phase 2 CALLIPER trial of vidofludimus calcium for progressive multiple sclerosis at the 2026 CMSC Annual Meeting.

Immunic, Inc. announced the appointment of Erik Lundgren as Chief Executive Officer, succeeding Daniel Vitt, Ph.D., who will remain on the Board and focus on scientific strategy.

Immunic, Inc. announced the appointment of Michael W. Bonney as Chair of its Board of Directors, effective May 16, 2026, bringing extensive biopharmaceutical leadership experience.

Immunic, Inc. announced first quarter 2026 financial results, highlighting progress in its Phase 3 ENSURE trials for vidofludimus calcium in multiple sclerosis and a significant private placement financing.

Immunic, Inc. announced the appointment of Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer, effective April 24, 2026, and the departure of Andreas Muehler, M.D., M.B.A.

Immunic, Inc. will implement a 1-for-10 reverse stock split, effective April 27, 2026, to meet contractual obligations and adjust its outstanding share count.

Immunic, Inc. stockholders approved a 1-for-10 reverse stock split, set to take effect on April 27, 2026, with new shares trading on Nasdaq the same day.

Immunic, Inc. announces a retention bonus agreement for CEO Daniel Vitt tied to the search for his successor.

Immunic, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, ensuring continued listing on The Nasdaq Capital Market.

Immunic, Inc. announced the appointment of Jon Congleton, a seasoned biopharmaceutical executive, to its Board of Directors, effective March 27, 2026, also naming him Chair of the Compensation Committee.

Immunic, Inc. announced its year-end 2025 financial results, a successful $200 million private placement, and key advancements in its multiple sclerosis clinical programs, targeting a 2028 regulatory approval for vidofludimus calcium.

Immunic, Inc. announced an oversubscribed private placement of up to $400 million, alongside significant board and executive leadership changes, to accelerate its transformation into a commercial-stage biotechnology company.

Immunic, Inc. has transferred its common stock listing to the Nasdaq Capital Market after failing to meet the $1.00 minimum bid price requirement, gaining an extended grace period until June 22, 2026.

Immunic, Inc. announces new employment agreements for Dr. Duane Nash and Dr. Daniel Vitt, redefining their roles and compensation structures.

Immunic, Inc. announced its third-quarter 2025 financial results and provided a corporate update, emphasizing positive clinical data for vidofludimus calcium in multiple sclerosis.

Immunic, Inc. announced positive data for vidofludimus calcium in progressive and relapsing-remitting multiple sclerosis at the 41st ECTRIMS Congress.

Immunic, Inc. announced positive Phase 2 clinical trial results for vidofludimus calcium in progressive multiple sclerosis and completed enrollment for its Phase 3 trials, alongside strengthening its balance sheet with recent financings.

Immunic, Inc. announced its Board of Directors authorized the grant of up to 35 million stock appreciation rights to employees and executive officers, contingent on shareholder approval to expand its equity incentive plan for share settlement.

Immunic, Inc. has received a formal notice from Nasdaq indicating non-compliance with the minimum bid price requirement, initiating a 180-day period to regain compliance or face potential delisting.

Immunic, Inc. announced that its stockholders approved an amendment to increase the shares authorized for its equity incentive plan by 7 million to a total of 26.4 million shares, alongside the re-election of three Class II Directors and the ratification of its independent auditor.

Immunic, Inc., a biotechnology company focused on inflammatory and autoimmune diseases, announced the pricing of an oversubscribed public offering expected to raise approximately $65 million initially, with potential for an additional $130 million from warrant exercises.

Immunic, Inc. has initiated an underwritten public offering of warrants to fund clinical trials and operations, while also announcing extended positive data from its Phase 2 CALLIPER trial for progressive multiple sclerosis.

Immunic's phase 2 CALLIPER trial indicates that vidofludimus calcium reduces the risk of disability worsening in patients with primary progressive multiple sclerosis.

Immunic, Inc. has announced a $5.1 million registered direct offering of common stock, led by Aberdeen Investments, to fund clinical trials and operations.

Immunic's IMU-856 demonstrated a dose-dependent increase in GLP-1 levels in celiac disease patients and reduced body weight gain in preclinical studies, suggesting potential as an oral treatment for weight management.

Immunic, Inc. released an updated corporate presentation on January 13, 2025, outlining its strategy, clinical programs, and financial outlook.